Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|January 9, 2010
18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapyDevin Schellenberg, Andy Quon, A Yuriko Minn, et al.Cancer|June 22, 2010
Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancerA Yuriko Minn, Annie Hsu, Trang La, et al.Endocrine-Related Cancer|March 24, 2022
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|March 24, 2016
A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates PrognosisGeorgios Antonios Margonis, Mario Samaha, Yuhree Kim, et al.Biorxiv : the Preprint Server for Biology|September 26, 2025
Epigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC ProfilingDejiang Wang, Xiangjun Di, Fu Gao, et al.International Journal of Radiation Oncology, Biology, Physics|December 27, 2011
Intensity-modulated radiotherapy for pancreatic adenocarcinomaJonathan A Abelson, James D Murphy, Ann Yuriko Minn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2018
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward Wolin, Beth Chasen, et al.Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.Clinical Therapeutics|October 28, 2017
Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat EthylLowell Anthony, Claire Ervin, Pablo Lapuerta, et al.Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.Pageof 3